International Urology and Nephrology

, Volume 24, Issue 2, pp 159–166 | Cite as

Effect of oral clodronate on bone pain

A controlled study in patients with metastic prostatic cancer
  • I. Elomaa
  • T. Kylmälä
  • T. Tammela
  • J. Viitanen
  • J. Ottelin
  • M. Ruutu
  • K. Jauhiainen
  • M. Ala-Opas
  • L. Roos
  • J. Seppänen
  • O. Alfthan


Although osteosclerotic metastases are characteristic of prostatic carcinoma, bone resorption is also accelerated. Since clodronate inhibits bone resorption and relieves bone pain, we have given it to patients with painful bone disease from prostatic cancer after failure of hormonal therapy. All patients received estramustine phosphate orally. Simultaneously they were randomly allocated to clodronate (36) and placebo (39) groups. Clodronate was given by mouth. The dose was 3.2 g for the first month, thereafter 1.6 g. Pain relief was more distinct in the clodronate group where one third of patients were totally free of bone pain. The use of analgesics stopped in 38% of patients on clodronate and in 18% on placebo which effect probably belongs to estramustine phosphate. Serum calcium concentration decreased more markedly in the clodronate group. Clodronate dose of 3.2 g seemed to be more potent than that of 1.6 g. Side effects were uncommon and occurred equally in both groups. No significant differences were seen in median survival or survival rates between the groups.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Klein, L. A.: Prostatic carcinoma.N. Engl. J. Med., 300, 824 (1979).PubMedCrossRefGoogle Scholar
  2. 2.
    Scott, W. W., Menon, M., Walsh, P. C.: Hormonal therapy of prostatic cancer.Cancer, 45, 1929 (1980).PubMedGoogle Scholar
  3. 3.
    Grayhack, J. T., Keeler, T. C., Kozlowski, J. M.: Carcinoma of the prostate: Hormonal therapy.Cancer, 60, 589 (1987).PubMedCrossRefGoogle Scholar
  4. 4.
    Elomaa, I., Kellokumpu-Lehtinen, P., Rannikko, S., Alfthan O.: Hormone resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments.Eur. Urol., 19, 12 (1991).PubMedGoogle Scholar
  5. 5.
    Murphy, G. P., Slack, N. H., Mittelman, T.: Experiences with estramustine phosphate in prostate cancer.Sem. Oncol., 10, 42 (1983).Google Scholar
  6. 6.
    Kontturi, M., Sotarauta, M., Tammela, T.: Sequentially alternating hormone chemotherapy with high-dose medroxyprogesterone acetate and low-dose epirubicin for treatment of hormone resistant metastatic prostatic cancer.Eur. Urol., 15, 43 (1988).PubMedGoogle Scholar
  7. 7.
    Fosså, S. D., Jahnsen, J. U., Karlsen, S.: High-dose medroxyprogesterone acetate versus prednisolone in hormone resistant prostatic cancer.Eur. Urol., 11, 11 (1985).PubMedGoogle Scholar
  8. 8.
    Elomaa, I., Taube, T., Blomqvist, C., Rissanen, P., Rannikko, S., Alfthan, O.: Aminoglutethimide in advanced prostatic cancer resistant to conventional hormonal therapy.Eur. Urol., 14, 104 (1988).PubMedGoogle Scholar
  9. 9.
    Adami, S., Salvagno, G., Bianchi, G., Dorizzi, R., Rosini, S., Mobilio, G., Lo Cascio, V.: Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton.J. Urol., 134, 1152 (1985).PubMedGoogle Scholar
  10. 10.
    Adami, S., Mian, M.: Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma.Recent Results in Cancer Res., 116, 67 (1989).Google Scholar
  11. 11.
    Lipton, A., Harvey, H., Givant, E., Lipton, N., Lynch, L., Seaman, J., Vandepol, C., Dellanno, D., Zelenakas, K.: Disodium pamidronate (ADP)—a dose seeking study in patients with breast and prostate cancer. In: R. D. Rubens (ed.): Management of Bone Metastases and Hypercalcaemia by Osteoclast Inhibition. Hofgrefe & Huber Publishers, Toronto-Lewiston N. Y.-Bern-Göttingen-Stuttgart 1989, pp. 90–100.Google Scholar
  12. 12.
    Clarke, N. V., McClure, J., George, J. R.: Subjective and metabolic effects of amino-hydroxypropylidene bisphosphonata (APD) in patients with advanced cancer of the prostate—preliminary report. In: R. D. Rubens (ed.): Management of Bone Metastases and Hypercalcaemia by Osteoclast Inhibition. Hogrefe & Huber Publishers, Toronto-Lewiston N.Y.-Bern-Göttingen-Stuttgart 1989, pp. 81–89.Google Scholar
  13. 13.
    Schmidt, J. D., Johnson, D. E., Scott, W. W., Gibbons, R. B., Prout, G. R., Murphy, G. P.: The National Prostatic Cancer Project: Chemotherapy of advanced prostatic cancer: evaluation of response parameters.Urology, 7, 602 (1976).PubMedCrossRefGoogle Scholar
  14. 14.
    Miller, A. B., Hoogstraten, B., Staquet, M., Winkler, A.: Reporting results of cancer treatment.Cancer, 47, 207 (1981).PubMedCrossRefGoogle Scholar
  15. 15.
    Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento A-L., Selander, K., Lamberg-Allardt, C., Holmström, T.: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.Lancet, 1, 146 (1983).PubMedCrossRefGoogle Scholar
  16. 16.
    Ascari, E., Attardo-Parrinello, G., Merlini, G.: Treatment of painful bone lesions and hypercalcemia.Eur. J. Haematol. Suppl. (51),43, 135 (1989).Google Scholar
  17. 17.
    Urwin, G. H., Percival, R. C., Harris, S., Beneton, M. N. C., Williams, J. L., Kanis, J. A.: Generalized increase in bone resorption in carcinoma of the prostate.Br. J. Urol., 57, 721 (1985).PubMedCrossRefGoogle Scholar
  18. 18.
    Percival, R. C., Watson, M. E., Williams, J. L., Kanis, J. A.: Carcinoma of the prostate: remission of paraparesis with inhibitor of bone resorption.Postgrad. Med. J., 61, 551 (1985).PubMedGoogle Scholar

Copyright information

© Akadémiai Kiadó 1992

Authors and Affiliations

  • I. Elomaa
    • 1
  • T. Kylmälä
    • 2
  • T. Tammela
    • 3
  • J. Viitanen
    • 4
  • J. Ottelin
    • 5
  • M. Ruutu
    • 6
  • K. Jauhiainen
    • 7
  • M. Ala-Opas
    • 8
  • L. Roos
    • 9
  • J. Seppänen
    • 10
  • O. Alfthan
    • 11
  1. 1.Department of Radiotherapy and OncologyUniversity of HelsinkiFinland
  2. 2.Central HospitalTampere UniversityFinland
  3. 3.Oulu University Central HospitalFinland
  4. 4.North-Karelia Central HospitalFinland
  5. 5.Kemi Central HospitalFinland
  6. 6.IVth Department of SurgeryUniversity of HelsinkiFinland
  7. 7.Mikkeli Central HospitalFinland
  8. 8.Hämeenlinna Central HospitalFinland
  9. 9.Leiras Clinical ResearchFinland
  10. 10.Tampere City HospitalFinland
  11. 11.IInd Department of Surgery, Urologic UnitUniversity of HelsinkiFinland

Personalised recommendations